MedTrace Logo

AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment

NCT01973569 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 679

Last updated 2020-02-12

Study results available
· View outcomes & findings →

Summary

To evaluate the inhibitory effect of progression, compared with placebo, in joint destruction by AMG 162 administered subcutaneously to rheumatoid arthritis participants.

Conditions

Interventions

DRUG

denosumab

denosumab administered subcutaneously

DRUG

placebo

placebo administered subcutaneously to match denosumab

Sponsors & Collaborators

Principal Investigators

  • Tsutomu Takeuchi, Prof. · Division of Rheumatology Department of Internal Medicine, Keio University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-12-31
Completion
2017-09-19

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01973569 on ClinicalTrials.gov